NovaBay Pharmaceuticals is a clinical-stage biotech company focused on the development of its proprietary and patented Aganocide® compounds. NBY focuses its technology on four therapeutic areas: dermatology, ophthalmology, urology and hospital infections. The company has entered into and recently expanded an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications. For further information, visit the company’s Web site at www.novabay.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: